Last reviewed · How we verify
NCT04790929: MuseCog
Assessing the Effects of the Muse Meditation System on Cognition and Well-being
NA trial testing Muse in Cognitive Change in 150 participants. Completed in 1 December 2022.
1 May 2022
Quick facts
| Lead sponsor | Western University, Canada |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 150 |
| Start date | 1 May 2021 |
| Primary completion | 1 May 2022 |
| Estimated completion | 1 December 2022 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Muse
- Meditation Coaching
Conditions studied
- Cognitive Change — all drugs for Cognitive Change →
Sponsor
Western University, Canada
Who can join
Adults 18 to 100, any sex, with Cognitive Change. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Interaxon markets a head-worn EEG biofeedback device ('Muse') to encourage and aid effective meditation and sleep. This device has been previously shown to improve workplace wellness, fatigue and quality of life, and performance on the Stroop Task. It has also been shown to improve physiological markers associated with improved relaxation. What is not known, is whether the use of the Muse devices can improve cognitive function. In this study, the investigators will examine whether use of the Muse Meditation system by healthy participants, leads to improvements in cognition, sleep quality, mindfulness, improvement in quality of life scores, reduction in perceived stress levels, and improvement in cognitive markers relevant for safety and increased success in the workplace.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04790929
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cognitive Change
Currently open trials in the same condition.
- NCT07147894 — Executive Function Training for Children and Adolescents · NA · recruiting
- NCT07383324 — Heat Stress in Individuals With Schizophrenia · NA · recruiting
- NCT07261202 — Impact of Indoor Overheating on Physiological Strain in Children · NA · recruiting
- NCT07267598 — Suitability of a 26 °C Indoor Environment for Mitigating Heat Strain in Young Adults · NA · recruiting
- NCT07054723 — Surviving Daily Life · recruiting
Other Western University, Canada trials
Trials by the same sponsor.
- NCT07485062 — Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes · Phase 4 · not yet recruiting
- NCT07372755 — Feasibility and Usability of a Mobile App for Monitoring and Managing Functional Movement Disorders · not yet recruiting
- NCT07302308 — Action Outcome Latencies as a Measure of Sense of Agency in Functional Movement Disorders. · not yet recruiting
- NCT04323423 — The DURATION Study: reDUcing sedentaRy behAviour to Maintain cogniTIve functiON. · NA · withdrawn
- NCT07204301 — Enhancing Patient Comfort and Reducing Anxiety During Flexible Cystoscopy and Bladder Instillation in Bladder Cancer Pat · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04790929 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Western University, Canada
- Last refreshed: 25 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04790929.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing